Yatra Online stock target cut to $3 at H.C. Wainwright, retains Buy rating
H.C. Wainwright analyst Scott Buck revised the price target on Yatra Online (NASDAQ:YTRA) to $3.00 from the previous $4.00, while maintaining a Buy rating on the company's stock. The adjustment ...
Arvinas price target lowered to $81 from $87 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Arvinas (ARVN) to $81 from $87 and keeps a Buy rating on the shares. Given the company’s ...
Sage Therapeutics price target lowered to $12 from $14 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Sage Therapeutics (SAGE) to $12 from $14 and keeps a Neutral rating on the shares. The ...
HC Wainwright Issues Pessimistic Forecast for XFOR Earnings
Investment analysts at HC Wainwright lowered their FY2028 earnings estimates for X4 Pharmaceuticals in a research note issued on Friday, February 7th. HC Wainwright analyst S. Ramakanth now forecasts ...
HC Wainwright Reiterates “Buy” Rating for 4D Molecular Therapeutics (NASDAQ:FDMT)
D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report)‘s stock had its “buy” rating reiterated by equities researchers at ...
Hosted on MSN1d
HC Wainwright & Co. Downgrades Pliant Therapeutics (PLRX)
Fintel reports that on February 10, 2025, HC Wainwright & Co. downgraded their outlook for Pliant Therapeutics (NasdaqGS:PLRX ...